IMTX
Immatics N.V.
Price Chart
Latest Quote
$9.59
+0.19 (+2.02%)
Current Price
| Previous Close | $9.40 |
| Open | $9.19 |
| Day High | $9.83 |
| Day Low | $9.19 |
| Volume | 393,663 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 136.67M |
| Total Debt | $17.26M |
| Cash Equivalents | $519.14M |
| Revenue | $42.69M |
| Net Income | $-245.40M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.31B |
| EPS (TTM) | $-1.99 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $872.21M |
| Sales | $42.69M |
| Income | $-245.40M |
| Book/sh | $3.81 |
| Cash/sh | $3.32 |
| Employees | 678 |
Financial Ratios
| Quick Ratio | 8.30 |
| Current Ratio | 8.78 |
| Debt/Eq | 3.31 |
Returns & Margins
| ROA | -22.44% |
| ROE | -43.21% |
| Operating Margin | -867.89% |
Ownership
| Insider Ownership | 17.58% |
| Institutional Ownership | 79.47% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.04 |
| P/S | 35.14 |
| P/B | 2.52 |
Analyst Data
| Recommendation | none |
| Target Price | $18.89 |
Technical Indicators
| SMA20 | $9.75 |
| SMA50 | $10.21 |
| SMA200 | $10.12 |
| RSI | 51.24 |
| ATR | 0.5279 |
| Shares Float | 69.59M |
| Short Float | 5.73% |
| Short Ratio | 10.25 |
| Volatility | 1.32 |
| Rel Volume | 0.98 |
Performance History
| Week | -0.93% |
| Month | +5.50% |
| Quarter | -11.78% |
| 6 Months | -2.44% |
| YTD | -8.23% |
| Year | +56.44% |
| 3 Years | -14.60% |
| 5 Years | -22.29% |
| 10 Years | -0.10% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $9.59 | 401,100 |
| 2026-07-16 | $9.40 | 343,300 |
| 2026-07-15 | $9.47 | 477,300 |
| 2026-07-14 | $9.35 | 194,600 |
| 2026-07-13 | $9.23 | 178,900 |
| 2026-07-10 | $9.68 | 264,100 |
| 2026-07-09 | $9.96 | 280,600 |
| 2026-07-08 | $9.98 | 448,800 |
| 2026-07-07 | $10.26 | 401,300 |
| 2026-07-06 | $9.99 | 837,200 |
| 2026-07-02 | $9.95 | 440,400 |
| 2026-07-01 | $9.85 | 270,400 |
| 2026-06-30 | $10.13 | 753,500 |
| 2026-06-29 | $9.56 | 331,300 |
| 2026-06-26 | $9.52 | 228,300 |
| 2026-06-25 | $9.52 | 289,800 |
| 2026-06-24 | $10.02 | 675,900 |
| 2026-06-23 | $9.91 | 347,300 |
| 2026-06-22 | $9.78 | 553,600 |
| 2026-06-18 | $9.78 | 438,400 |
About Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in TÃŧbingen, Germany.
đ° Latest News
Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results
Simply Wall St. âĸ 2026-05-15T10:59:38Z
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-12T12:25:02Z
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Zacks âĸ 2026-05-07T15:42:00Z
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Zacks âĸ 2026-05-07T15:35:00Z
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Zacks âĸ 2026-05-07T15:30:00Z
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T15:15:08Z
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
Zacks âĸ 2026-05-06T16:00:06Z
Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-04T12:25:02Z
Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside
Simply Wall St. âĸ 2026-03-15T20:06:37Z
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate
Insider Monkey âĸ 2026-03-13T18:31:53Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $55,243,217 | $178,362,134 | $61,802,677 | $197,815,035 |
| Operating Revenue | $55,243,217 | $178,362,134 | $61,802,677 | $197,815,035 |
| Expenses | ||||
| Interest Expense | $1,082,751 | $1,014,078 | $951,127 | $1,188,051 |
| Total Expenses | $263,571,013 | $222,559,225 | $178,232,799 | $163,530,956 |
| Other Income Expense | $-37,373,239 | $41,027,812 | $-9,480,371 | $12,182,671 |
| Net Non Operating Interest Income Expense | $18,579,604 | $27,601,007 | $14,895,273 | $1,645,874 |
| Interest Expense Non Operating | $1,082,751 | $1,014,078 | $951,127 | $1,188,051 |
| Operating Expense | $263,571,013 | $222,559,225 | $178,232,799 | $163,530,956 |
| Other Operating Expenses | $-5,418,336 | $-89,275 | $-1,303,651 | $-29,758 |
| General And Administrative Expense | $58,583,036 | $53,163,556 | $43,719,811 | $41,345,999 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-224,844,907 | $17,417,878 | $-108,331,232 | $31,707,679 |
| Net Interest Income | $18,579,604 | $27,601,007 | $14,895,273 | $1,645,874 |
| Interest Income | $19,662,355 | $28,615,085 | $15,846,400 | $2,833,925 |
| Normalized Income | $-187,846,274 | $-11,831,689 | $-99,080,066 | $23,678,929 |
| Net Income From Continuing And Discontinued Operation | $-224,844,907 | $17,417,878 | $-108,331,232 | $31,707,679 |
| Total Operating Income As Reported | $-208,327,796 | $-44,197,092 | $-116,430,122 | $34,284,078 |
| Net Income Common Stockholders | $-224,844,907 | $17,417,878 | $-108,331,232 | $31,707,679 |
| Net Income | $-224,844,907 | $17,417,878 | $-108,331,232 | $31,707,679 |
| Net Income Including Noncontrolling Interests | $-224,844,907 | $17,417,878 | $-108,331,232 | $31,707,679 |
| Net Income Continuous Operations | $-224,844,907 | $17,417,878 | $-108,331,232 | $31,707,679 |
| Pretax Income | $-227,121,432 | $24,431,727 | $-111,015,220 | $48,112,623 |
| Interest Income Non Operating | $19,662,355 | $28,615,085 | $15,846,400 | $2,833,925 |
| Operating Income | $-208,327,796 | $-44,197,092 | $-116,430,122 | $34,284,078 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-1.84 | $0.16 | $-1.35 | $0.63 |
| Basic EPS | $-1.84 | $0.16 | $-1.35 | $0.64 |
| Other | ||||
| Tax Effect Of Unusual Items | $-374,606 | $11,778,246 | $-229,205 | $4,153,921 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-174,472,927 | $-1,589,791 | $-92,303,992 | $45,092,136 |
| Total Unusual Items | $-37,373,239 | $41,027,812 | $-9,480,371 | $12,182,671 |
| Total Unusual Items Excluding Goodwill | $-37,373,239 | $41,027,812 | $-9,480,371 | $12,182,671 |
| Reconciled Depreciation | $14,192,514 | $13,992,217 | $8,279,730 | $7,974,133 |
| EBITDA (Bullshit earnings) | $-211,846,166 | $39,438,021 | $-101,784,363 | $57,274,807 |
| EBIT | $-226,038,680 | $25,445,805 | $-110,064,092 | $49,300,674 |
| Diluted Average Shares | $140,034,830 | $122,233,143 | $92,190,317 | $78,067,153 |
| Basic Average Shares | $140,034,830 | $121,031,162 | $92,190,317 | $76,673,096 |
| Diluted NI Availto Com Stockholders | $-224,844,907 | $17,417,878 | $-108,331,232 | $31,707,679 |
| Tax Provision | $-2,276,525 | $7,013,849 | $-2,683,988 | $16,404,944 |
| Gain On Sale Of Security | $-37,373,239 | $41,027,812 | $-9,480,371 | $12,182,671 |
| Research And Development | $210,406,313 | $169,484,945 | $135,816,638 | $122,214,716 |
| Selling General And Administration | $58,583,036 | $53,163,556 | $43,719,811 | $41,345,999 |
| Other Gand A | $28,497,195 | $26,283,621 | $43,719,811 | $41,345,999 |
| Salaries And Wages | $30,085,841 | $26,879,935 | $24,928,465 | $23,947,579 |
| Minority Interests | - | - | - | $0 |
| Restructuring And Mergern Acquisition | - | - | - | $0 |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $552,268,499 | $656,075,296 | $247,333,175 | $230,881,304 |
| Total Assets | $643,627,087 | $796,779,195 | $583,684,316 | $466,773,480 |
| Total Non Current Assets | $66,760,900 | $76,217,235 | $69,354,468 | $35,099,003 |
| Other Non Current Assets | $880,165 | $1,049,559 | $690,168 | $2,912,899 |
| Non Current Prepaid Assets | $1,237,267 | $381,138 | $1,618,404 | $2,181,527 |
| Goodwill And Other Intangible Assets | $1,810,690 | $1,864,484 | $1,743,161 | $1,867,918 |
| Other Intangible Assets | $1,810,690 | $1,864,484 | $1,743,161 | $1,867,918 |
| Current Assets | $576,866,187 | $720,561,960 | $514,329,849 | $431,674,477 |
| Other Current Assets | $17,019,572 | $7,222,158 | $8,148,106 | $15,838,388 |
| Prepaid Assets | $14,787,684 | $13,789,630 | $12,154,057 | $11,960,627 |
| Receivables | $7,875,701 | $7,720,041 | $6,566,327 | $1,271,603 |
| Taxes Receivable | $895,044 | $1,016,367 | $1,881,653 | $1,180,039 |
| Accounts Receivable | $6,980,657 | $6,703,674 | $4,684,674 | $1,271,603 |
| Cash Cash Equivalents And Short Term Investments | $537,183,230 | $691,830,130 | $487,461,359 | $414,564,486 |
| Cash And Cash Equivalents | $395,923,076 | $270,971,723 | $250,053,788 | $169,988,550 |
| Hedging Assets Current | - | - | - | - |
| Other Receivables | - | - | - | - |
| Debt | ||||
| Total Debt | $17,895,158 | $18,545,267 | $17,628,476 | $16,667,048 |
| Long Term Debt And Capital Lease Obligation | $14,739,613 | $15,282,133 | $14,648,048 | $14,195,948 |
| Current Debt And Capital Lease Obligation | $3,155,545 | $3,263,134 | $2,980,428 | $2,471,100 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $89,547,898 | $138,839,415 | $334,607,981 | $234,024,259 |
| Total Non Current Liabilities Net Minority Interest | $40,318,186 | $61,024,378 | $155,425,199 | $112,183,813 |
| Non Current Deferred Liabilities | $25,578,573 | $45,742,244 | $140,772,573 | $97,939,794 |
| Non Current Deferred Taxes Liabilities | $4,357,331 | $6,643,012 | $8,545,267 | $11,229,255 |
| Current Liabilities | $49,229,711 | $77,815,038 | $179,182,781 | $121,840,446 |
| Other Current Liabilities | $1,774,064 | $3,647,705 | $21,982,373 | $30,078,974 |
| Current Deferred Liabilities | $18,102,323 | $41,098,774 | $114,914,728 | $74,347,028 |
| Payables And Accrued Expenses | $24,244,019 | $27,998,168 | $37,843,652 | $14,943,344 |
| Payables | $3,078,860 | $15,887,604 | $17,768,112 | $14,943,344 |
| Total Tax Payable | $2,689,710 | $4,313,838 | $8,993,934 | $8,840,563 |
| Income Tax Payable | $36,626 | $2,015,566 | $4,919,309 | $4,919,309 |
| Accounts Payable | $389,150 | $11,573,766 | $8,774,179 | $14,943,344 |
| Other Non Current Liabilities | - | - | $4,578 | $48,071 |
| Equity | ||||
| Common Stock Equity | $554,079,190 | $657,939,780 | $249,076,336 | $232,749,222 |
| Total Equity Gross Minority Interest | $554,079,190 | $657,939,780 | $249,076,336 | $232,749,222 |
| Stockholders Equity | $554,079,190 | $657,939,780 | $249,076,336 | $232,749,222 |
| Gains Losses Not Affecting Retained Earnings | $-9,834,039 | $1,180,039 | $-1,872,496 | $-1,695,090 |
| Other Equity Adjustments | $-9,834,039 | $1,180,039 | $-1,872,496 | $-1,695,090 |
| Retained Earnings | $-899,608,539 | $-674,763,632 | $-692,181,510 | $-583,850,277 |
| Other | ||||
| Ordinary Shares Number | $153,452,476 | $139,121,170 | $96,895,716 | $87,754,031 |
| Share Issued | $153,452,476 | $139,121,170 | $96,895,716 | $87,754,031 |
| Tangible Book Value | $552,268,499 | $656,075,296 | $247,333,175 | $230,881,304 |
| Invested Capital | $554,079,190 | $657,939,780 | $249,076,336 | $232,749,222 |
| Working Capital | $527,636,475 | $642,746,922 | $335,147,067 | $309,834,031 |
| Capital Lease Obligations | $17,895,158 | $18,545,267 | $17,628,476 | $16,667,048 |
| Total Capitalization | $554,079,190 | $657,939,780 | $249,076,336 | $232,749,222 |
| Additional Paid In Capital | $1,461,986,916 | $1,330,131,591 | $942,160,901 | $817,416,713 |
| Capital Stock | $1,534,852 | $1,391,782 | $969,440 | $877,876 |
| Common Stock | $1,534,852 | $1,391,782 | $969,440 | $877,876 |
| Non Current Deferred Revenue | $21,221,242 | $39,099,232 | $132,227,306 | $86,710,539 |
| Long Term Capital Lease Obligation | $14,739,613 | $15,282,133 | $14,648,048 | $14,195,948 |
| Current Deferred Revenue | $18,102,323 | $41,098,774 | $114,914,728 | $74,347,028 |
| Current Capital Lease Obligation | $3,155,545 | $3,263,134 | $2,980,428 | $2,471,100 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,953,760 | $1,807,256 | $1,461,600 | $922,513 |
| Current Accrued Expenses | $21,165,159 | $12,110,564 | $20,075,540 | $11,114,799 |
| Net PPE | $62,832,779 | $72,922,054 | $65,302,734 | $30,318,186 |
| Accumulated Depreciation | $-34,065,468 | $-36,697,950 | $-26,170,310 | $-23,442,829 |
| Gross PPE | $96,898,246 | $109,620,004 | $91,473,043 | $53,761,015 |
| Leases | $32,922,055 | $35,958,566 | $29,086,642 | $4,390,523 |
| Other Properties | $39,384,227 | $44,040,287 | $35,033,764 | $40,592,880 |
| Machinery Furniture Equipment | $10,184,274 | $14,565,640 | $12,646,217 | $8,777,612 |
| Buildings And Improvements | $14,407,691 | $15,055,511 | $14,706,421 | $14,202,815 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $141,260,154 | $420,858,408 | $237,407,571 | $244,575,935 |
| Current Provisions | - | - | - | - |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-209,947,345 | $-199,736,747 | $-14,569,074 | $107,492,272 |
| Operating Activities | ||||
| Operating Cash Flow | $-202,158,631 | $-180,874,438 | $20,862,996 | $114,605,697 |
| Cash Flow From Continuing Operating Activities | $-202,158,631 | $-180,874,438 | $20,862,996 | $114,605,697 |
| Operating Gains Losses | $37,944,374 | $-41,168,592 | $10,060,661 | $-9,147,304 |
| Investing Activities | ||||
| Capital Expenditure | $-7,788,714 | $-18,862,309 | $-35,432,070 | $-7,113,425 |
| Investing Cash Flow | $234,390,517 | $-174,415,699 | $-35,925,374 | $-240,117,883 |
| Cash Flow From Continuing Investing Activities | $234,390,517 | $-174,415,699 | $-35,925,374 | $-240,117,883 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $122,822,476 | $392,594,702 | $103,472,585 | $153,924,684 |
| Financing Cash Flow | $111,426,116 | $365,896,752 | $96,733,430 | $141,593,221 |
| Cash Flow From Continuing Financing Activities | $111,426,116 | $365,896,752 | $96,733,430 | $141,593,221 |
| Net Other Financing Charges | $-8,009,614 | $-24,395,101 | $-2,333,753 | $-9,077,486 |
| Net Common Stock Issuance | $122,822,476 | $392,594,702 | $103,472,585 | $153,924,684 |
| Common Stock Issuance | $122,822,476 | $392,594,702 | $103,472,585 | $153,924,684 |
| Other | ||||
| Repayment Of Debt | $-3,386,746 | $-2,302,850 | $-4,405,402 | $-3,253,977 |
| End Cash Position | $395,923,076 | $270,971,723 | $250,053,788 | $169,988,550 |
| Beginning Cash Position | $270,971,723 | $250,053,788 | $169,988,550 | $152,219,293 |
| Effect Of Exchange Rate Changes | $-18,706,649 | $10,311,319 | $-1,605,814 | $1,688,222 |
| Changes In Cash | $143,658,003 | $10,606,615 | $81,671,052 | $16,081,034 |
| Net Issuance Payments Of Debt | $-3,386,746 | $-2,302,850 | $-4,405,402 | $-3,253,977 |
| Net Long Term Debt Issuance | $-3,386,746 | $-2,302,850 | $-4,405,402 | $-3,253,977 |
| Long Term Debt Payments | $-3,386,746 | $-2,302,850 | $-4,405,402 | $-3,253,977 |
| Net Investment Purchase And Sale | $242,179,232 | $-155,555,679 | $-664,988 | $-233,063,975 |
| Sale Of Investment | $629,345,297 | $359,894,692 | $474,698,397 | $14,530,159 |
| Purchase Of Investment | $-387,166,066 | $-515,450,371 | $-475,363,385 | $-247,594,134 |
| Net Intangibles Purchase And Sale | $-282,706 | $-238,068 | $-180,840 | $-545,954 |
| Purchase Of Intangibles | $-282,706 | $-238,068 | $-180,840 | $-545,954 |
| Net PPE Purchase And Sale | $-7,506,009 | $-18,621,952 | $-35,079,546 | $-6,507,955 |
| Sale Of PPE | $0 | $2,289 | $171,684 | $59,517 |
| Purchase Of PPE | $-7,506,009 | $-18,624,241 | $-35,251,230 | $-6,567,472 |
| Taxes Refund Paid | $-5,070,390 | $-14,991,415 | $-3,387,890 | $-256,381 |
| Interest Received Cfo | $30,693,601 | $17,860,821 | $11,636,717 | $1,887,375 |
| Interest Paid Cfo | $-1,082,751 | $-1,014,078 | $-331,922 | $-795,468 |
| Change In Working Capital | $-50,320,475 | $-172,576,395 | $96,818,127 | $42,643,927 |
| Change In Other Working Capital | $-43,052,534 | $-171,389,489 | $98,430,809 | $52,144,900 |
| Change In Other Current Assets | $-6,990,958 | $832,093 | $1,800,389 | $-9,009,957 |
| Change In Receivables | $-276,983 | $-2,019,000 | $-3,413,071 | $-491,015 |
| Changes In Account Receivables | $-276,983 | $-2,019,000 | $-3,413,071 | $-491,015 |
| Other Non Cash Items | $-18,579,604 | $-27,601,007 | $-14,895,273 | $-1,645,874 |
| Stock Based Compensation | $17,185,532 | $20,192,285 | $23,698,065 | $25,832,665 |
| Deferred Tax | $-2,276,525 | $7,013,849 | $-2,683,988 | $16,404,944 |
| Deferred Income Tax | $-2,276,525 | $7,013,849 | $-2,683,988 | $16,404,944 |
| Depreciation Amortization Depletion | $14,192,514 | $13,992,217 | $8,279,730 | $7,974,133 |
| Depreciation And Amortization | $14,192,514 | $13,992,217 | $8,279,730 | $7,974,133 |
| Gain Loss On Investment Securities | $-1,980,085 | $-19,759,642 | $2,379,535 | $-12,527,183 |
| Net Foreign Currency Exchange Gain Loss | $39,066,040 | $-21,410,094 | $7,852,810 | $3,379,879 |
| Gain Loss On Sale Of PPE | $858,418 | $1,145 | $-171,684 | $0 |
| Net Income From Continuing Operations | $-224,844,907 | $17,417,878 | $-108,331,232 | $31,707,679 |
| Change In Payables And Accrued Expense | - | - | - | - |
| Change In Payable | - | - | - | - |
| Change In Account Payable | - | - | - | - |
Fetched: 2026-07-15